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AbstrACt
Although therapeutic hypothermia (TH) is the standard 
of care for hypoxic ischaemic encephalopathy in high-
income countries, the safety and efficacy of this therapy 
in low-income and middle-income countries (LMICs) 
is unknown. We aimed to describe the feasibility of TH 
using a low-cost servo-controlled cooling device and the 
short-term outcomes of the cooled babies in LMIC.
Design We recruited babies with moderate or severe 
hypoxic ischaemic encephalopathy (aged <6 hours) 
admitted to public sector tertiary neonatal units in India 
over a 28-month period. We administered whole-body 
cooling (set core temperature 33.5°C) using a servo-
controlled device for 72 hours, followed by passive 
rewarming. We collected the data on short-term neonatal 
outcomes prior to hospital discharge.
results Eighty-two babies were included—61 (74%) 
had moderate and 21 (26%) had severe encephalopathy. 
Mean (SD) hypothermia cooling induction time was 
1.7 hour (1.5) and the effective cooling time 95% (0.08). 
The mean (SD) hypothermia induction time was 1.7 hour 
(1.5 hour), core temperature during cooling was 33.4°C 
(0.2), rewarming rate was 0.34°C (0.16°C) per hour and 
the effective cooling time was 95% (8%). Twenty-five 
(51%) babies had gastric bleeds, 6 (12%) had pulmonary 
bleeds and 21 (27%) had meconium on delivery. Fifteen 
(18%) babies died before discharge from hospital. Heart 
rate more than 120 bpm during cooling (P=0.01) and 
gastric bleeds (P<0.001) were associated with neonatal 
mortality.
Conclusions The low-cost servo-controlled cooling 
device maintained the core temperature well within 
the target range. Adequately powered clinical trials are 
required to establish the safety and efficacy of TH in 
LMICs.
Clinical trial registration number NCT01760629. 
Hypoxic ischaemic encephalopathy (HIE) 
accounts for 1 million infant deaths every year, 
and more than half of the surviving infants 
develop lifelong neurodisability.1 Thera-
peutic hypothermia (TH) reduces mortality 
and improves survival with normal neurolog-
ical outcome after HIE in high-income coun-
tries2–5 and is now offered as standard care in 
these settings.6 
There are several challenges in extrapo-
lating the safety and efficacy data of cooling 
therapy from high-income countries to low-in-
come and middle-income countries (LMICs), 
which shoulder 99% of the disease burden.1 
What is already known on this topic?
 ► Therapeutic hypothermia (TH) improves 
neurodevelopmental outcomes after moderate or 
severe neonatal encephalopathy in high-income 
countries.
 ► Core temperature needs to be maintained within a 
narrow target range for optimal neuroprotection.
What this study hopes to add?
 ► Effective TH can be provided using a low-cost 
servo-controlled cooling device in low-income and 
middle-income countries.
 ► Bleeding problems, particularly gastric bleeds, 
frequently occur in babies with encephalopathy 
undergoing cooling therapy in these settings and 
are associated with high mortality.
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First, the population comorbidities are very different, 
and there is far higher incidence of foetal growth restric-
tion, meconium aspiration and perinatal sepsis in LMICs; 
these may reduce the neuroprotective effect of cooling. 
Second, in high-income countries, cooling is provided 
only in specialist cooling centres with facilities for optimal 
intensive care support and with high nursing to patient 
ratios. Such facilities and staffing resourcing levels are not 
available in most LMIC neonatal units. Finally, for effec-
tive neuroprotection, it is essential to rapidly reduce the 
core body temperature and precisely maintain this within 
the target range (33°C to 34°C) for 72 hours. Deviations 
from these regimes with overcooling or undercooling, or 
prolonging the duration of therapy, may be potentially 
harmful.7 Thus, in high-income countries, TH is adminis-
tered using sophisticated and expensive servo-controlled 
devices,8 which are unaffordable in LMICs.
Despite the lack of evidence, TH is an increasingly 
used routine clinical practice in LMIC. A recent survey 
of cooling practices in India9 suggested that most units 
offering cooling therapy use various improvised local 
solutions including air conditioning, ice packs and phase-
changing materials to manually achieve cooling, but the 
efficacy of these methods is still debatable, and they may 
be associated with increased monitoring and staffing 
requirements.8 Here, we report the feasibility and effec-
tiveness of using an affordable servo-controlled system 
for whole-body cooling in public sector neonatal units in 
India and the short-term outcomes of the cooled babies.
MethoDs
We recruited term babies (aged <6 hours; birth weight 
≥1.8 kg) requiring resuscitation at birth and with 
moderate or severe HIE, from five large public sector 
hospitals in India (Madras Medical College, Chennai; 
Indira Gandhi Institute of Child Health, Bangalore; 
Lokmanya Tilak Municipal General Hospital, Mumbai; 
Jawaharlal Nehru Institute of Postgraduate Medical 
Education and Research, Puducherry and Government 
Medical College, Calicut), between April 2013 and 
August 2015. These hospitals are funded by the Indian 
government and offer free healthcare to low-income 
populations. All centres are regional neonatal intensive 
care units with facilities for cardiorespiratory support and 
neonatal surgery. However, invasive blood pressure moni-
toring, inhaled nitric oxide and amplitude-integrated 
electroencephalography (aEEG) are not available. We 
trained the medical staff at the recruiting centres in 
the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) neurolog-
ical staging of neonatal encephalopathy (table 1) prior 
to the start of the study.2
We excluded babies who were born in moribund condi-
tion, as well as those who had any major life-threatening 
congenital malformations, or if the cooling device was 
not available (ie, already in use) at the time of recruit-
ment. The University College London ethics committee 
and the ethics committee of each participating hospital 
approved the study. We obtained informed parental 
consent prior to recruitment.
Procedures
We initiated cooling by keeping the baby naked with a 
nappy on the cooling mattress, inserting a core tempera-
ture monitoring probe, turning off radiant warmers and 
switching on the machine (Tecotherm HELIX, Inspira-
tion Healthcare) (figure 1). The device had a single set 
temperature of 33.5°C. Following a rapid induction phase, 
the device maintained core body temperature between 
33°C and 34°C for 72 hours, servo-controlled to rectal or 
oesophageal temperature. After 72 hours of cooling, we 
removed the mattress and rewarmed the baby passively 
using three layers of clothing, without using a radiant 
warmer. Once the baby’s temperature reached 36.5°C, we 
restarted the overhead radiant warmer (servo-controlled 
to avoid hyperthermia). We documented the vital param-
eters every 15 min during the first hour and then hourly 
until 90 hours after the start of cooling.
Clinical management protocols were unaltered by study 
participation. We monitored the haemogram, biochem-
istry, blood cultures (where available) and liver function 
throughout the first 4 days. We obtained antenatal and 
delivery data on all babies. We also collected data on 
medications (antibiotics, anticonvulsants, inotropes and 
sedatives), ventilation and the use of blood products up 
to hospital discharge.
sample size and statistical analysis
We expected the cooling device to have comparable 
efficacy to the standard servo-controlled cooling device 
used in high-income countries—that is, over 90% effec-
tive cooling time (percentage of time during which the 
rectal temperature is effectively within the target temper-
ature (33°C to 34°C) during the entire cooling period).8 
Assuming an effective cooling time of 90%, to estimate 
this percentage with an uncertainty of ±7% (with a 95% 
confidence level), 74 babies needed to be recruited. We 
increased the sample size to 82 to allow for a 10% rate of 
early mortality (prior to the completion of cooling).
The associations between clinical variables and 
mortality were examined. The unpaired t-test or Mann-
Whitney test was used to compare the continuous vari-
ables between survivors and non-survivors, whereas 
Fisher’s exact test was used to compare categorical vari-
ables between groups. We used IBM SPSS (V.24; IBM, 
New York, USA) and STATA (V.15; StataCorp, Texas, 
USA) for all data analysis.
results
Out of 173 babies screened, 91 did not meet the eligibility 
criteria (age >6 hours; mild encephalopathy; non-availa-
bility of the device). We enrolled the remaining 82 into 
this study after informed parental consent (49 babies 
from Institute of Child Health, Madras Medical College, 
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Chennai; 14 babies from Indira Gandhi Institute of 
Child Health, Bangalore; 10 babies from Lokmanya 
Tilak Municipal General Hospital, Mumbai; 9 babies 
from Jawaharlal Nehru Institute of Postgraduate Medical 
Education and Research, Puducherry). Sixty-one (74%) 
babies had moderate and 21 (26%) had severe encepha-
lopathy. Fifteen (18%) babies died before discharge from 
hospital (5 (8%) babies with moderate encephalopathy 
and 10 (47%) with severe encephalopathy).
Overall, 19 (24%) babies were inborn at the recruiting 
centre, 57 (73%) were born at another hospital and 2 
(3%) were born at home. The majority of babies (66%–
85%) were born via spontaneous vaginal delivery, 8 
(9.8%) via emergency caesarean section, 2 (3%) via 
non-emergency caesarean section and 2 (3%) via instru-
mental vaginal delivery. The mean (SD) maternal age was 
22.8 (2.9) years, and mean gestational age was 38.7 (1.3) 
weeks. Mean birth weight was 2901 (365) g and head 
circumference 33.7 (0.7) cm. Mean (SD) Apgar scores 
were 4.5 (1.3) at 5 min and 6.3 (1) at 20 min. Sixty-four 
babies were men (65%).
Clinical seizures were present within the first 6 hours in 
68 (87%) babies. Pregnancy complications were reported 
in 5 (7%) cases and delivery complications in 9 (12%). 
Meconium stained liquor was reported in 19 (27%) 
babies and maternal fever during labour occurred in 3 
(4%) cases. The baseline characteristics of survivors and 
non-survivors are given in table 2.
therapeutic effectiveness of the cooling device
Mean (SD) age at the start of cooling was 3.7 (1.4) hours. 
Target cooling temperature was achieved within 1 hour 
of start of cooling in 37 (45%) of the babies and within 
2 hours for 63 (77%) of the babies. Three babies (4%) 
Table 1 Classification of neonatal encephalopathy (NICHD neurological examination)
Categories (total 6)
Signs of NE in each category (circle the most appropriate level)
 Normal Mild NE Moderate NE Severe NE
1. Level of consciousness
Alert, responsive to 
external stimuli (state 
dependent,  
eg, postfeeds)
Hyperalert, has a stare, 
jitteriness, high-pitched 
cry, exaggerated 
responds to minimal 
stimuli, inconsolable
Lethargic Stupor/coma
2. Spontaneous activity
Changes position  
when awake
Normal or decreased Decreased activity No activity
3. Posture
Predominantly flexed 
when quiet
Mild flexion of distal 
joints (fingers, wrist 
usually)
Moderate flexion of 
distal joint, complete 
extension
Decerebrate
4. Tone
Strong flexor tone in  
all extremities+strong  
flexor hip tone
Normal or slightly 
increased peripheral 
tone
Hypotonia (focal or 
general) or hypertonia
Flaccid
rigid
5. Primitive reflexes (circle only the highest level in each sign; the maximum score is only one in any one category)
  Suck Strong, easily illicit Weak, poor Weak but has a bite Absent
  Moro Complete Partial response, low 
threshold to illicit
Incomplete Absent
6. Autonomic system (circle only the highest level in each sign; the maximum score is only one in any one category)
  Pupils In dark: 2.5–4.5 mm
In light: 1.5–2.5 mm
Mydriasis Constricted Deviation/dilated/non-
reactive to light
  Heart rate 100–160 bpm Tachycardia (HR >160) Bradycardia (HR <100) Variable HR
  Respiration Regular respirations Hyperventilation (RR 
>60/min)
Periodic breathing Apnoea or requires 
ventilator
Total score
  *Seizure None None Yes/no Yes/no
Infant who has seizure will be moderate or severe NE depending on the neurological exam. Seizure with normal or mild NE or moderate NE 
on neurological exam will be ‘moderate NE’. Seizure with severe NE will be ‘severe NE’. The level of encephalopathy will be assigned based 
on which level of signs (moderate or severe) predominates among the six categories. If moderate and severe signs are equally distributed, the 
designation is then based on the highest level in category no 1: the level of consciousness.
HR, heart rate; NE, neonatal encephalopathy; NICHD, National Institute of Child Health and Human Development; RR, regular respiration.
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took more than 3 hours to reach target cooling temper-
ature. The mean (SD) baseline temperature before start 
of cooling was 35.5°C (1.5), and babies took on average 
1.7 hour (1.5) to reach target temperature range (defined 
as time at which core temperature dropped below 34°C).
During cooling treatment, mean (SD) temperature 
was 33.4°C (0.24), and cooling phase lasted on average 
72.2 hours (2.1). Time within target core temperature 
(effective cooling time) of 33°C to 34°C was 95% (0.08). 
Passive rewarming phase lasted on average 11.3 hours 
(5.8) with an average rewarming rate of 0.34°C (0.16) per 
hour. Of 71 babies, 35 (50%) took more than 10 hours 
to reach normothermia. Rectal temperature probes were 
used in 75 babies (91%), and oesophageal probes were 
used in 7 babies (9%). The effectiveness during cooling 
and rewarming is presented in figure 2.
Clinical status and ongoing care
The majority of babies were on intravenous (only) fluids 
for the first 4 days (varying from 76 (93%) on day 1 to 
Figure 1 Setting up of Tecotherm HELIX cooling device.
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54 (66%) on day 4). Three babies (4%) received enteral 
feeds via nasogastric tube on day 1 and, by day 4, there 
were 2 (2%) babies on full nasogastric feeds and 17 
(21%) receiving a combination of intravenous plus naso-
gastric intake.
Thirty-seven babies (46%) required invasive ventilation 
during the first 24 hours. Most babies required treatment 
with anticonvulsive drugs (59 (77%) on day 1 to 52 (72%) 
on day 4), using mainly phenobarbitone (53% on day 1 
to 64% of the babies on day 4) or multiple drugs (13% 
to 18% of the babies). Sixty-three (82%) babies required 
some inotropic support on day 1, decreasing to 48 babies 
(68%) on day 4. Main inotropes used were a combina-
tion of dopamine and dobutamine. Requirement of 
Table 2 Baseline characteristics of survivors and non-survivors
Survivors
(n=67) Non-survivors (n=15) P values
Maternal age (years) 22.6±3.0 24.0±1.8 0.37
Gestational age (weeks) 38.8±1.3 38.0±1.2 0.14
Age at start of cooling (hours) 3.6±1.4 4.1±1.4 0.22
Birth weight (g) 2912±364 2855±388 0.58
Head circumference (cm) 33.7±0.8 33.9±0.4 0.49
1 min Apgar—median (IQR) 1 (0) 2 (2) 0.33
5 min Apgar— median (IQR) 4 (0) 4.5 (2) 0.60
10 min Apgar— median (IQR) 5.0 (0) 5.0 (0) 0.36
20 min Apgar— median (IQR) 7.0 (0) NA –
Gender (male) 45/66 (68%) 8/15 (53%) 0.37
Severe encephalopathy 11/67 (16%) 10/15 (67%) <0.001
Seizures within 6 hours of birth 55/64 (86%) 13/14 (93%) 0.68
Complications in pregnancy 4/64 (6%) 1/12 (8%) 1.00
Complications during delivery 9/64 (14%) 0/13 (0%) 0.34
Meconium stained liquor 13/60 (22%) 6/11 (55%) 0.06
Maternal fever during labour 2/64 (3%) 1/13 (8%) 0.43
Place of delivery
  Inborn 15/65 (23%) 4/13 (31%)
  Outborn— hospital 48/65 (74%) 9/13 (69%) 0.81
  Outborn— home 2/65 (3%) 0/13 (0%)
Delivery method
  Prelabour LSCS 2/65 (3%) 0/13 (0%)
  Emergency LSCS 6/65 (9%) 2/13 (15%) 0.82
  Spontaneous vaginal delivery 55/65 (85%) 13/13 (85%)
  Instrumental vaginal delivery 2/65 (3%) 0/13 (0%)
Neonatal complications
  Gastric bleeds 14/38 (37%) 11/11 (100%) <0.001
  Pulmonary haemorrhage 1/38 (3%) 5/11 (45%) 0.001
  PPHN 1/38 (3%) 6/11 (55%) <0.001
  Thrombocytopenia 42/67 (63%) 10/15 (67%) 1.00
  Metabolic acidosis 26/67 (39%) 9/15 (60%) 0.16
Treatment duration (days)
  Invasive ventilation 1.4±1.8 3.3±1.5 0.002
  Sedation 0.9±1.5 1.4±1.8 0.40
  Inotropic support 3.1±1.3 3.9±0.3 0.04
  Anticonvulsive drugs 2.9±1.7 3.9±0.3 0.07
LSCS, lower segment caesarean section; PPHN, persistent pulmonary hypertension.
Mean values ± SD or proportion (percentage), unless specified otherwise.
 o
n
 24 April 2018 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2017-000245 on 23 March 2018. Downloaded from 
6 Oliveira V, et al. BMJ Paediatrics Open 2018;2:e000245. doi:10.1136/bmjpo-2017-000245
Open Access
inotropic support during the first 4 days was higher for 
non-survivors (mean 3.9 days vs 3.0 days, P=0.000, 95% 
CI (−1.64 to −0.3)), but only 25% (12/48) of babies 
requiring inotropic support on day 4 died. Sedation was 
used in 22 (37%) babies. This corresponded to 14 (19%), 
18 (25%), 17 (24% and 18 (26%) between days 1 and 4, 
respectively). When using sedation, choral hydrate and 
fentanyl were the preferred sedatives (53% and 41%, 
respectively).
The mean (SD) heart rate of the babies who died was 
121 bpm (17 bpm), which was higher than those who 
survived, who had a mean (SD) heart rate of 111 bpm (13 
bpm) (P=0.008) (figure 2). The babies who died were 
more likely to have a heart rate higher than 120 bpm 
(93% vs 51%; P=0.005) and more persistently elevated 
heart rate (>120 bpm) (median of 5 hours compared with 
a median of 1 hour) than those who survived (P=0.01). 
Duration of heart rate above 120 bpm did not appear to 
be associated with sedation or sedation days, neither did 
sedation (lack of) seem to be associated with mortality. 
Figure 3 presents the average heart rate during treatment.
Only one baby had hypoglycaemia (blood sugar level 
below 45 mg/dL (2.5 mmol/L)), which occurred on 
day 1. Metabolic acidosis (absolute base excess <−10) 
persisted for more than 24 hours in 4 (13%) babies. 
Fifty-two babies (64%) had thrombocytopenia (platelet 
count below 100 x 109/L). C reactive protein was avail-
able only for 20 babies, and the mean (SD) on days 1 to 
4 were 4.8 (3.0), 8.4 (12.8), 22.9 (22.1) and 48.6 (62.7), 
respectively. There was no growth in any of the 49 blood 
cultures (automated) obtained at the time of recruiting.
Gastric bleed (defined as fresh blood >5 mL from naso-
gastric tube) was recorded in 25/49 (51%) and pulmo-
nary haemorrhage (defined as copious bloody secretions 
with clinical deterioration requiring change(s) in ventila-
tory management) in 6/49 (12%) of the babies (table 3). 
There was no significant difference between those with 
and without gastric bleeds for any of birth weight, seda-
tion or severity of encephalopathy. However, there was 
a highly significant association between gastric bleeds 
and mortality. No patients without gastric bleeds died, 
whereas almost half (44%) of patients with a gastric bleed 
died. The bleeds were treated with blood product trans-
fusions (fresh frozen plasma, packed cell transfusions 
and platelets).
Persistent pulmonary hypertension (defined as severe 
hypoxaemia disproportionate to the severity of lung 
disease with a significant pre–postductal saturation differ-
ence on pulse oximetry) occurred in 7/49 (14%) of the 
babies. Persistent pulmonary hypertension was managed 
by vasopressors and by optimising conventional ventila-
tion. Inhaled nitric oxide was not available.
DisCussion
The data presented here have several important messages 
for the clinicians in LMICs and will inform the design of 
future cooling trials in these settings. First, TH can be 
effectively delivered using a low-cost servo-controlled 
whole-body cooling device without the need for addi-
tional nursing resources. Whereas concerns about the 
loss of therapeutic effectiveness and increased workload 
associated with high oscillations during manual cooling 
have been described previously,8 the effective cooling 
times achieved in our study were reassuring that a low-cost 
servo-controlled cooling device may offer a promising 
alternative. In addition, a high thermal efficacy and 
stability of the device used in this study suggests that this 
method may not only hold better therapeutic effect but 
also sustain or even reduce staff demand. As the study 
used a pragmatic approach, the treatment requirements 
and decisions were continued from what had been locally 
practised until the study. Although we have not formally 
collected feedback from staff on the challenges of deliv-
ering TH, we observed a fast-paced learning curve which 
was facilitated by the ease of operation of a simplified 
Figure 2 Mean (SD—error bars) temperature during cooling 
and rewarming.
Figure 3 Mean (SD—error bars) heart rate (bpm) during 
cooling and rewarming. The dotted line represents non-
survivors, and the continuous line represents survivors.
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equipment, suggesting there was no increase in the 
required intensity of care.
Our servo-controlled device is based on Tecotherm-Neo, 
a widely used whole-body cooling device in high-income 
countries. Although the device has similar safety features, 
cost reduction was achieved by simplifying the design with 
a single set target temperature of 33.5°C. The coolant 
was tap water, mixed with locally available surgical spirit 
(90% alcohol). The device lacked a rewarming mode, 
hence the rewarming was passive by removing the baby 
from the cooling mattress. This increased the rewarming 
duration and the variability of core temperature during 
rewarming. The device has been modified to include a 
constant rewarming since then and is currently being 
CE (Conformité Européene) marked. It is likely that the 
eventual costs (approximately US$1000) of this device 
would be one-tenth of high-income country cooling 
devices.
Second, the short clinical term morbidity of babies with 
encephalopathy in this setting was different to high-in-
come countries. There was a very high incidence of 
gastric bleeds (25/49, 51%), although we did not have 
data on gastric bleeds for all the participants and we had 
data for more non-survivors than survivors. The reason 
for gastric bleeds is unclear, and none of the babies had 
evidence of perforation or necrotising enterocolitis. It is 
possible that the bleeds were multiple in utero ischaemic 
events; however, no relation with birth weight and gastric 
bleed was seen on regression model. There was no rela-
tion of sedation and gastric bleeds indicating that stress 
of cooling was an unlikely contributor to these bleeds.
Coagulopathy is a well-known complication of hypoxic 
ischaemic encephalopathy, and gastrointestinal bleeding 
has been reported in up to 25% of the babies undergoing 
TH in high-income countries.10 11 Cooling studies from 
LMICs have not yet reported such bleeds as yet. In these 
settings, it is possible that gastric bleeds were not specif-
ically looked for or recorded in the case record forms 
and hence were overlooked. The incidence of pulmonary 
bleed was also much higher than the published data from 
high-income countries.12
We also observed a persistently higher heart rate above 
120 bpm during cooling in non-survivors, which was 
independent of sedative use. Association of tachycardia 
during cooling and increased mortality in neonatal 
encephalopathy has been reported previously.13 It is 
possible that this elevated heart rate is a reflection of the 
underlying disease severity and cardiac dysfunction.
There are several limitations of this feasibility study. We 
were unable to perform autopsy in any of the babies due 
to a lack of parental consent and, hence, were unable to 
find the cause of the gastric bleeds. As there was no control 
arm, it is unclear if the gastric bleeds were related to the 
underlying condition or to the cooling therapy. Although 
blood cultures were obtained, we have not performed 
detailed screening for infection using polymerise chain 
reaction methods, and hence we might have missed coex-
istent sepsis. Finally, we have not performed any neuro-
imaging or assessed the neurodevelopmental outcomes.
A number of small randomised controlled trials of 
cooling therapy have been reported from LMIC. The 
pooled data from these studies do not suggest an improve-
ment in neonatal mortality.14 Only one of these studies 
had reported neurodevelopment outcomes at 18 months 
or more, and the authors claimed that cooling signifi-
cantly reduced death and neurodisability.15 An indigenous 
(China) servo-controlled head cooling device was used in 
this study. This study was of poor quality, and relevance of 
the findings remains unclear. Since then, one more pilot 
randomised control involving 60 encephalopathy babies 
(30 each allocated to cooling and usual care) from India 
has been reported. Authors claimed adverse outcomes 
(death or neurodisability at 30 months) in 6/30 (20%) 
of cooled babies and 18/30 (60%) of usual care babies 
(P=0.0015). Adverse outcomes related to cooling were 
minimal. Selective head cooling was attempted using 
ice in this study, which had been previously shown to be 
unreliable in administrating effective TH.16 Hence, it is 
unclear if any survival benefits in this study were related 
to the intervention.
Most studies in LMICs have used water bottles, ice or 
frozen gels pack to induce TH.17–22 While such manual 
methods are suitable and safe when there is close nursing 
monitoring to ensure that core temperature is main-
tained in the target range,23 most LMIC neonatal units 
do not have adequate nursing resources. We have previ-
ously reported the use of phase change material for TH in 
India.24 Given that the phase change materials are inex-
pensive (US$20) and widely available, cooling devices 
can be easily developed from these. However, in our 
experience, the cooling efficacy of phase change mate-
rials was weak and required low ambient temperatures to 
induce cooling, which limits the wider use.24 Neverthe-
less, cooling devices using phase change material is now 
commercially marketed in India, and several centres are 
using these devices.25
Table 3 Comparison of babies with encephalopathy with and without gastric bleeds
Variable
No gastric bleed Gastric bleed
P values
Mean/proportion 
difference (95% CIs)n Summary n Summary
Mean (SD) birth weight (g) 24 2925±249 25 2967±386 0.66 42 (228 to −146)
Sedation during cooling 19 4 (21%) 18 5 (28%) 0.71 7% (−20% to 33%)
Mortality 24 0 (0%) 25 11 (44%) <0.001 44% (22% to 63%)
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Considering the differences in comorbidities, maternal 
ill health and healthcare resources in LMICs, adequately 
powered and designed clinical trials are required to 
answer the question of whether TH is safe and beneficial 
for babies with moderate or severe encephalopathy in 
these settings.7 Despite the lack of evidence, many centres 
in India and other LMICs are now routinely offering 
cooling therapy to babies with neonatal encephalopathy 
using a wide range of indigenous cooling devices.9
The data presented in this feasibility study will inform 
the study design of future cooling trials in LMIC. Our 
inclusion criteria were purely clinical so as to increase the 
generalisability of the therapy in LMIC, where blood gas 
and aEEG are not routinely available. A large pragmatic 
trial of hypothermia for neonatal encephalopathy is 
currently underway in India, Bangladesh and Sri Lanka.26 
A total of 408 babies with moderate and severe enceph-
alopathy will be randomised to whole-body cooling 
using a servo-controlled cooling device or usual care. All 
babies have detailed infection screen and 3 Tesla MRI 
and spectroscopy in addition to detailed neurodevelop-
mental assessment at 18 months. The study protocol of 
the HELIX trial is available online and may be useful for 
clinicians in LMIC who wish to offer TH in these settings.
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